Altogether these results lend support to the use of [18F]FDDNP PET as a tool for imaging changes in PSP-tau pathology, although researchers caution this use due to the tracer’s lack of specificity. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.